Citi initiates coverage on AMAG Pharmaceuticals (Nasdaq: AMAG) with a Buy. Price target $37.

Citi analyst says, "Feraheme’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE